Placebo cream + Ketoconazole 2% cream (formulation F012) (Nizoral) + Ketoconazole 2% cream (formulation F126)
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Tinea Pedis
Conditions
Tinea Pedis
Trial Timeline
Jul 1, 2007 → Oct 1, 2008
NCT ID
NCT01110330About Placebo cream + Ketoconazole 2% cream (formulation F012) (Nizoral) + Ketoconazole 2% cream (formulation F126)
Placebo cream + Ketoconazole 2% cream (formulation F012) (Nizoral) + Ketoconazole 2% cream (formulation F126) is a phase 3 stage product being developed by Johnson & Johnson for Tinea Pedis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01110330. Target conditions include Tinea Pedis.
What happened to similar drugs?
3 of 10 similar drugs in Tinea Pedis were approved
Approved (3) Terminated (0) Active (7)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01110330 | Phase 3 | Terminated |
Competing Products
20 competing products in Tinea Pedis